Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Description
T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy
